Pharmacodynamics EBB/DHPA has been said to have relatively weak estrogenic activity and has been described as "progestogen-dominant". Pharmacokinetics EBB is said to have a shorter duration than estradiol enantate of about 3 weeks. EBB/DHPA was developed because it was thought that the duration of EBB would be more suitable for use as a once-monthly combined injectable contraceptive than estradiol enantate in estradiol enantate/algestone<unk> .
Estradiol benzoate butyrate/algestone acetophenide
Estradiol enantate/algestone acetophenide
Estradiol benzoate/estradiol dienanthate/testosterone enanthate benzilic acid hydrazone
Testosterone propionate/testosterone cypionate/prasterone
Testosterone propionate/testosterone enanthate
Estradiol benzoate/progesterone/testosterone propionate
Testosterone propionate/testosterone ketolaurate
Testosterone propionate/testosterone enanthate/testosterone undecylenate